Biomarkers in Drug Design

\r\n The discovery and evaluation of any novel biomarkers will ideally be specialized to Clinical Laboratory Improvement Amendments (CLIA) and Good Clinical Laboratory Practice (GCLP) standards, so as to ensure accuracy and reproducibility of laboratory procedures. Predictive biomarkers indicate the likelihood of response to a specific antitumor therapy. Such assays should be scientifically sound, Predictive biomarkers include both tumor-specific and surrogate biomarkers, and are crucial to accelerating the drug development process

\r\n

\r\n  

\r\n
  • Biomarker Discovery for Immuno-Oncology Agents
  • Biomarkers in Drug Design & Clinical Trial
  • Dose-Selection Biomarkers
  • Biomarkers of Toxicity & Pharmacology
  • Biomarkers of Efficacy

Related Conference of Biomarkers in Drug Design

Biomarkers in Drug Design Conference Speakers